Study #2020-0255
ACCRU-ICRN-1702: A Phase II Study of Olaparib in Patients with Advanced Biliary Tract Cancer with Aberrant DNA Repair Gene Mutations
MD Anderson Study Status
Enrolling
Treatment Agent
Olaparib
Description
This phase II trial studies how well olaparib works in treating patients with biliary tract cancer that has spread to other places in the body (metastatic) and with aberrant DNA repair gene mutations. Olaparib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth.
Resources and Links
Phone Number: 1-877-MDA-6789
Information and next steps
Disease:
Bile Duct Adenocarcinoma, Fanconi Anemia Complementation Group Gene Mutation, Metastatic Bile Duct Carcinoma, PTEN Gene Deletion
Study phase:
Phase II
Physician name:
Milind Javle
Department:
Gastrointestinal Medical Oncology
For general questions about clinical trials:
1-877-934-6089
Help #EndCancer
Give Now
Donate Blood
Our patients depend on blood and platelet donations.
Shop MD Anderson
Show your support for our mission through branded merchandise.